Synergy's Trulance effective in older chronic idiopathic constipation, IBS-C patients — 5 insights

A series of studies confirmed Synergy Pharmaceuticals' Trulance was effective in older patients with chronic idiopathic constipation or irritable bowel syndrome with constipation.

The company presented the findings at ACG 2018, Oct. 5-10 in Philadelphia.

Here's what you should know:

1. Researchers conducted four phase 3 trials. They tested Trulance in adults more than 65 years old with CIC and IBS-C.

2. Trulance was both safe and tolerable in patients aged 65 years old and older, with results comparable to a younger cohort.

3. Adverse events were similar between the two cohorts.

4. Synergy also conducted two studies testing Synergy in CIC patients receiving concomitant acid suppression therapy. In this study, 883 patients received Trulance and 892 received a placebo. Ten percent of the combined cohorts were receiving acid suppression therapy. Efficacy and safety results were similar to the overall population.

5. Synergy CMO Patrick Griffin, MD, said, "We are excited to provide healthcare professionals with new evidence to further reinforce Trulance as an efficacious treatment option with a strong safety profile for patients aged 65 years and older, as well as for patients who require concomitant acid suppression therapy."

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast